Publication: Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8
No Thumbnail Available
Identifiers
Date
2022-05-05
Authors
Jerusalem, G.
Prat, A.
Salgado, R. F.
Reinisch, M.
Saura, C.
Ruiz Borrego, M.
Nikolinakos, P.
Filian, J.
Ades, F.
Huang, N.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
